Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00570778 · ClinicalTrials.gov registry record · Phase 2
Efficacy and Safety of QVA149 in Patients With Chronic Obstructive Pulmonary Disease (COPD)
A Phase 2 study, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 154
- Enrollment target
NCT00570778: Completed Phase 2 study, sponsored by Novartis Pharmaceuticals.
NCT00570778 is a Phase 2 study that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 154 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (16% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00570778, a Phase 2 study, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 154 participants
- Enrollment target
Study Summary
This study will evaluate the safety and efficacy of QVA149 in patients with moderate to severe COPD.
Primary Outcome
Spirometry testing was performed in accordance with American Thoracic Society standards. Trough FEV1 was defined as the average of the 23 hour 15 minute and 23 hour 45 minute measurements post dosing. Baseline FEV1 is the mean of the 45 minute and 15 minute pre-dose FEV1 values at day 1 of each period. Least square means are based on the Analysis of Covariance Trough FEV1 at day 7 = sequence effect + patient(sequence) + period effect + treatment effect + (period) baseline FEV1 + error.
Interventions
- DRUG placebo
- DRUG indacaterol/glycopyrrolate
- DRUG indacaterol
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 154 participants |
| Start Date | 2007-12 |
| Est. Completion | 2008-09 |
| Phase | Phase 2 |
What the finished NCT00570778 record still lists
NCT00570778 is an interventional study that assigns participants to a tested intervention. The registered 154 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (16% higher).
The record links to 0 conditions, and to 3 interventions - of which placebo is the first listed.
NCT00570778 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00570778 about?
NCT00570778 is a clinical study titled "Efficacy and Safety of QVA149 in Patients With Chronic Obstructive Pulmonary Disease (COPD)". This study will evaluate the safety and efficacy of QVA149 in patients with moderate to severe COPD.
What is the current status of trial NCT00570778?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 154 participants. The study started on 2007-12. Estimated completion is 2008-09.
What interventions are being tested in trial NCT00570778?
The interventions under investigation include: placebo (DRUG), indacaterol/glycopyrrolate (DRUG), indacaterol (DRUG).
Who is sponsoring clinical trial NCT00570778?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00570778's enrollment target sits among peer trials
154 448th of 2000 higher than 1,552 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04300998 · 154 participants
Study of CAR-T Therapy in Older Patients
- NCT04597372 · 154 participants · Phase 2
Impact of Tamsulosin on Post-Operative Urinary Retention Following Pelvic Reconstructive Surgery
- NCT05294042 · 154 participants · NA
Patient Navigators for Children's Community Mental Health Services in High Poverty Urban Communities
- NCT05512390 · 154 participants · Phase 1
A Study to Assess the Adverse Events, Change in Disease Activity, and How Intravenously Infused ABBV-319 Moves Through the Bodies of Adult Participants With Relapsed or Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL), Follicular Lymphoma (FL), or Chronic Lymphocytic Leukemia (CLL)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia